Profile
Jeffery L.
Kutok held several positions throughout his career.
He was an Associate Professor-Pathology at The Brigham & Women's Hospital, Inc. and Harvard Medical School from 2002 to 2010.
He then became the Chief Scientific Officer & Senior Vice President at Infinity Pharmaceuticals, Inc. from 2010 to 2020.
After that, he was the Chief Scientific Officer & Executive VP at Epizyme, Inc. from 2020 to 2022.
Kutok received his undergraduate, graduate, and doctorate degrees from Stony Brook University.
Former positions of Jeffery L. Kutok
| Companies | Position | End |
|---|---|---|
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 2022-08-31 |
| INFINITY PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2020-03-30 |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Corporate Officer/Principal | 2010-11-30 |
| Harvard Medical School | Corporate Officer/Principal | 2010-11-30 |
Training of Jeffery L. Kutok
| Stony Brook University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
The Brigham & Women's Hospital, Inc.
The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Jeffery L. Kutok
